RxDoctor Payments DataLook up a doctor →

Edward Allegra, MD

Rheumatology · Red Bank, NJNPI 1588665913

Payments from drug & device makers

$211,526in general payments, 2019–2025

Across 2,559 payments — averaging $82.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$126K
  • Pfizer$26K
  • E.r. Squibb & Sons, L.L.C.$19K
  • Amgen$8K
  • Johnson & Johnson$8K
  • Sanofi$7K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$3,1481%
  • Speaking & faculty fees$173,68682%
  • Travel & lodging$2,2371%
  • Food & beverage$31,49415%
  • Education$9620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie451$125,655
Pfizer321$25,569
E.r. Squibb & Sons, L.L.C.134$19,209
Amgen(2 entities)373$8,455
Johnson & Johnson(2 entities)366$7,784
Sanofi43$6,966
Bristol Myers Squibb25$3,425
Regeneron Healthcare Solutions, Inc.6$2,809
Novartis119$1,514
AstraZeneca(2 entities)74$1,476
Genentech USA, Inc.99$1,067
UCB, Inc.76$1,048
Mallinckrodt Hospital Products Inc.63$911
GSK60$855
Lilly USA, LLC38$495
ANI Pharmaceuticals, Inc.38$478
Pacira Pharmaceuticals Incorporated29$415
Collegium Pharmaceutical, Inc.33$403
Aurinia Pharma U.S., Inc.27$399
Organon19$280
Radius Health, Inc.9$170
Sanofi-aventis U.S. LLC3$166
Sandoz8$136
Zyla Life Sciences, Inc.21$127
Daiichi Sankyo Inc.12$118
Fresenius Kabi USA, LLC6$101
Idorsia Pharmaceuticals US Inc6$95
Cumberland Pharmaceuticals, Inc.4$85
Hikma Pharmaceuticals USA6$77
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$77
Phathom Pharmaceuticals, Inc.5$73
Vanda Pharmaceuticals Inc.5$70
Boehringer Ingelheim5$70
Mallinckrodt Enterprises LLC5$68
MDD US Operations, LLC4$54
Pacira Therapeutics, Inc.4$53
Si-bone, Inc.3$53
IBSA Pharma Inc.4$51
Medexus Pharma, Inc.4$48
Scilex Pharmaceuticals Inc.3$48
Takeda Pharmaceuticals U.S.A., Inc.4$43
Sobi, Inc3$43
Kowa Pharmaceuticals America, Inc.3$40
Tonix Medicines, Inc.2$38
Invivyd Inc2$34
Vertex2$32
Almatica Pharma LLC2$30
Assertio Therapeutics, Inc.2$28
Kiniksa Pharmaceuticals, Ltd.2$26
Ferring Pharmaceuticals Inc.2$26
Eisai Inc.2$26
Fidia Pharma USA Inc.2$25
Tersera Therapeutics LLC2$25
Aytu Biopharma, Inc.2$25
Kyowa Kirin, Inc.1$19
Bayer1$15
Merck1$14
Celltrion USA Inc.1$13
Vertical Pharmaceuticals, LLC1$13
Arbor Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$211,526 in reported general payments places this provider in the 90th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$4,867,793
Medicare patients
995
Services billed
453,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab99$1,026,388
Enbrel SureclickEtanercept57$557,299
Simponi AriaGolimumab77$510,920
Xeljanz XrTofacitinib Citrate77$431,292
EnbrelEtanercept33$259,312
Cimzia (2 Pack)Certolizumab Pegol41$244,881
RinvoqUpadacitinib35$215,848
OrenciaAbatacept/Maltose27$134,165
XeljanzTofacitinib Citrate17$98,881
RayosPrednisone30$88,851
Orencia ClickjectAbatacept12$66,199
OtezlaApremilast12$66,094
ActemraTocilizumab18$59,057
RemicadeInfliximab13$58,667
ProliaDenosumab31$53,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi Aria, Remicade$7,784$569,58890 claims
AmgenEnbrel, Rayos, Otezla, Prolia$8,455$468,046106 claims
UCB, Inc.Cimzia (2 Pack)$1,048$244,88141 claims
AbbVieRinvoq$125,655$215,84835 claims
E.r. Squibb & Sons, L.L.C.Orencia$19,209$134,16527 claims
PfizerXeljanz$25,569$98,88117 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$403$29,90333 claims
Medexus Pharma, Inc.Rasuvo$48$20,50816 claims
Scilex Pharmaceuticals Inc.Colchicine$48$3,68737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Red Bank

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →